The Alliance for Aging Research and a distinguished panel of experts will discuss the recent recommendations by MedPAC and MACPAC – the advisory committees for Medicare and Medicaid – and the Institute for Clinical and Economic Review (ICER) to restrict reimbursement to drugs and devices approved via the Food and Drug Administration’s Accelerated Approval Pathway.
In this conversation, we explore the role of accelerated approval, its impact on the Medicare/Medicaid budgets, and the care community at large, as well as the access issues that will inevitably stem from these coverage challenges.
source
